CAR-T Therapies Market, 2030 - Robust Development Pipeline

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
45
CAR-T Therapies Market, 2030 - Robust Development Pipeline Following Recent Approval of Kymriah (Novartis) and Yescarta (Gilead Sciences)

Dublin, Aug. 30, 2018 (GLOBE NEWSWIRE) -- The "CAR-T Therapies Market, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The "CAR-T Therapies Market, 2018-2030" report features an extensive study of the current market landscape and the future potential of CAR-T therapies. One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms.

Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory. Close to 70 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Given the recent approval of two CAR-T therapies, namely Kymriah (Novartis) and Yescarta (Gilead Sciences), and a robust development pipeline, the CAR-T therapy market also offers considerable promise to a number of industry stakeholders. Amongst other elements, the report features the following:

  • An analysis depicting prevalent and emerging trends related to CAR-T therapies as observed on the social media platform, Twitter. In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates as well.
  • A detailed assessment of the current market landscape of CAR-T therapies with respect to type of developer (industry and non-industry), phase of development, target therapeutic indications, key target antigens, source of T-cells (autologous and allogenic), and route of administration (intravenous infusion and regional route).
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process of the therapy (wherever available).
  • An analysis of the CAR constructs of clinical stage therapies based on generation of CAR-T product (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA electroporation, sleeping beauty and other vectors) and type of co-stimulatory domain used.
  • An analysis of the CAR-T clinical trials registered across the world in the period between 2009 and 2018, highlighting the year wise trend and the geographical distribution.
  • A detailed analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of CAR-T therapies.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of CAR-T therapies, along with profiles of key technology providers.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies, featuring different models / approaches that a pharmaceutical company may choose to adopt to decide the price of its proprietary products that are likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T therapies, Kymriah and Yescarta.

The report features detailed transcripts of interviews held with the following individuals:

  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital).

Key Topics Covered:

1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Pillars of Cancer Therapy 3.3. Immunotherapy, an Emerging Therapeutic Option 3.4. Fundamentals of Cancer Immunotherapy 3.5. Classification of Cancer Immunotherapies 3.5.1. By Mechanism of Action 3.5.1.1. Active Immunotherapy 3.5.1.2. Passive Immunotherapy 3.5.2. By Type of Target 3.5.3. By Approach 3.5.3.1. Activation and Suppression Immunotherapy 3.5.4. By Product Class 3.5.4.1. Monoclonal Antibodies 3.5.4.2. Bispecific Antibodies 3.5.4.3. Cytokines 3.5.4.4. Oncolytic Virus Therapy 3.5.4.5. Therapeutic Cancer Vaccines 3.5.4.6. Cell Based Therapies 3.6. Evolution of T-Cell Immunotherapies 3.7. Key Considerations for T-Cell Immunotherapies 3.8. Strategies Employed for Redirection of T-Cells 3.9. Manufacturing of Engineered T-Cells 3.10. T-Cell Transduction / Transfection Methods 3.10.1. Retroviral Vectors 3.10.2. Lentiviral Vectors 3.10.3. Non-viral Transfection Methods 3.10.3.1. Sleeping Beauty Transposon 3.11. T-Cell Immunotherapy: Targeted Therapeutic Areas 3.12. T-Cell Immunotherapies: Key Challenges 4. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY 4.1. Chapter Overview 4.2. History of Development 4.3. Anatomical Layout of Chimeric Antigen Receptor 4.4. Development Of CAR-T Therapies 4.5. Universal CAR-Ts 4.6. Preferred Routes of Administration 4.7. Toxicity Issues 4.7.1. Cytokine Release Syndrome (CRS) 4.7.2. On-Target, Off-Tumor Toxicity 4.7.3. Encephalopathy and B-Cell Aplasia 4.7.4. Neurological Toxicity 4.7.5. Anaphylaxis 4.7.6. Insertional Oncogenesis 4.7.7. Graft versus Host Disease (GVHD) 4.8. Management of Toxicity Issues 4.8.1. Pharmacological Immunosuppression 4.8.2. Target Selection 4.8.3. Safety Switches 4.8.4. Elimination Genes 4.8.5. Receptor Expression 4.9. CD19: An Attractive Target 4.10. Other Targets 4.11. Challenges Associated with CAR-T Therapy 4.11.1. Competitive Risks 4.11.2. Clinical Risks 4.11.3. Regulatory Risks 4.11.4. Commercial Risks 5. EMERGING TRENDS ON SOCIAL MEDIA 5.1. Chapter Overview 5.2. Trends on Twitter 5.2.1. Social Media Analysis: Yearly Trends on Twitter 5.2.2. Social Media Analysis: Popular Keywords on Twitter 5.3. Social Media Analysis: Most Popular Drugs on Twitter 6. MARKET LANDSCAPE 6.1. Chapter Overview 6.2. CAR-T Therapies: Pipeline Overview 6.2.1. Distribution by Type of Developer 6.2.2. Distribution by Phase of Development 6.2.3. Target Oncological Indications 6.2.3.1. Popular Target Indications 6.2.4. Popular Target Antigens 6.2.5. Distribution by Source of T-Cells 6.2.6. Distribution by Route of Administration 6.2.7. Key Industry Players 6.2.8. Key Non-Industry Players 6.3. CAR-T Therapies: Analysis of CAR Constructs 6.3.1. Analysis by Generation of CAR-T Therapies 6.3.2. Analysis by Type of scFv Antibody 6.3.3. Analysis by Type of Vector 6.3.4. Analysis by Type of Co-Stimulatory Domain(s) 7. KEY INSIGHTS 7.1. Chapter Overview 7.2. CAR-T Therapies: Analysis by Popularity of Target Antigens 7.2.1. Hematological Cancers: Popular Targets 7.2.1.1. CD19 CAR-T Therapies: Competitive Landscape 7.2.1.2. CD19 CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates 7.2.1.3. BCMA CAR-T Therapies: Competitive Landscape 7.2.1.4. BCMA CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates 7.2.2. Solid Tumors: Popular Targets 7.2.2.1. Meso CAR-T Therapies: Competitive Landscape 7.2.2.2. GD2 CAR-T Therapies: Competitive Landscape 7.3. CAR-T Therapies: Clinical Trial Trends, 2009-2018 7.3.1. Analysis by Trial Registration Year 7.3.2. Geographical Analysis by Number of Registered Trials 7.4. CAR-T Therapies: Clinical Trial Overview 7.4.1. Clinical Trial Analysis: Distribution by Phase of Development 7.4.2. Clinical Trial Analysis: Distribution by Patient Segment 7.4.3. Clinical Trial Analysis: Distribution by Type of Therapy 7.5. CAR-T Therapies: Key Opinion Leaders 7.5.1. Most Prominent Key Opinion Leaders 8. MARKETED AND LATE-STAGE CAR-T THERAPY PROFILES 8.1. Chapter Overview 8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis) 8.2.1. Therapy Overview 8.2.2. History of Development 8.2.3. Current Development Status 8.2.4. Key Clinical Trial Results 8.2.5. Dosage Regimen, Price and Manufacturing 8.3. Yescarta / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma) 8.3.1. Therapy Overview 8.3.2. Current Development Status 8.3.3. Key Clinical Trial Results 8.3.4. Dosage Regimen, Price and Manufacturing 8.3.5. Next Generation eACT CAR Candidates 8.4. JCAR (Juno Therapeutics) 8.4.1. Therapy Overview 8.4.2. CAR-T Design 8.4.3. Development Status 8.4.4. Key Clinical Results 8.4.4.1. JCAR014 8.4.4.2. JCAR017 8.4.4.3. JCAR018 8.4.5. Dosage Regimen and Manufacturing 8.5. CAR-T Series (Cellular Biomedicine Group) 8.5.1. Therapy Overview 8.5.2. History of Development 8.5.3. Current Development Status 8.5.4. Key Clinical Trial Results 8.5.4.1. CBM-EGFR.1 8.5.4.2. CBM-C19.1 8.5.4.1. CBM-C20.1 8.5.4.2. CBM-C30.1 8.5.5. Dosage Regimen and Manufacturing 8.5.6. Patent Portfolio 8.6. CD19 CAR (Takara Bio) 8.6.1. Therapy Overview 8.6.2. Current Developmental Status 8.6.3. Key Clinical Trial Results 8.6.4. Dosage Regimen and Manufacturing 8.7. Dual Targeting CAR-T Cell therapies (Autolus) 8.7.1. Therapy Overview 8.7.2. Current Development Status 8.7.3. Key Clinical Trial Results 8.7.4. Dosage Regimen and Manufacturing 8.8. CAR-T Therapies (Sinobioway Cell Therapy) 8.8.1. Therapy Overview 8.8.2. Current Development Status 9. KEY THERAPEUTIC AREAS CAR-T THERAPIES 9.1. Chapter Overview 9.2. Hematological Malignancies 9.2.1. Leukemia and Lymphoma 9.2.1.1. Leukemia: Introduction and Epidemiology 9.2.1.1.1. Acute Myeloid Leukemia (AML) 9.2.1.1.2. Chronic Myeloid Leukemia (CML) 9.2.1.1.3. Acute Lymphocytic Leukemia (ALL) 9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL) 9.2.1.2. Lymphoma: Introduction and Epidemiology 9.2.1.3. Current Treatment Landscape 9.2.1.3.1. Targeted Therapies 9.2.1.4. CAR-T Therapy and Research Landscape 9.2.2. Multiple Myeloma 9.2.2.1. Introduction and Epidemiology 9.2.2.2. Current Treatment Landscape 9.2.2.3. CAR-T Therapy and Research Landscape 9.3. Solid Tumors 9.3.1. Metastatic Melanoma 9.3.2. Lung Cancer 9.3.3. Bladder Cancer 9.3.4. Kidney Cancer 9.3.5. Ovarian Cancer 9.3.6. Breast Cancer 10. EMERGING TECHNOLOGIES 10.1. Chapter Overview 10.2. Genome Editing Technologies 10.2.1. Technology Overview 10.2.2. Applications 10.2.3. Emerging Technology Platforms Used in CAR-T Therapies 10.2.3.1. CRISPR/Cas9 System 10.2.3.1.1. Key Components and Function 10.2.3.1.2. Mechanism of Action 10.2.3.1.3. Targeting Efficiency and Challenges 10.2.3.1.4. Next-GEN CRISPR Technology 10.2.3.1.5. Technology Providers 10.2.3.2. TALENs 10.2.3.2.1. Key Components and Function 10.2.3.2.2. Mechanism of Action 10.2.3.2.3. Advantages and Challenges 10.2.3.2.4. Technology Providers 10.2.3.3. megaTAL 10.2.3.3.1. Technology Providers 10.2.3.4. Zinc Finger Nuclease 10.2.3.4.1. Technology Providers 10.3. Designing T-Cell Therapies with Improved Characteristics 10.3.1. Technologies for Targeting Multiple Cancers 10.3.1.1. NKR-T Platform (Celyad) 10.3.2. Technologies for Improved Safety 10.3.2.1. Armored CAR and EGFRt technology (Juno Therapeutics) 10.3.2.2. RheoSwitch Therapeutic System (Intrexon) 10.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals) 10.3.2.3.1. CaspaCIDe Technology 10.3.2.3.2. CIDeCAR Technology 10.3.2.3.3. GoCAR-T Technology 10.3.2.4. On-Off Switch, Multiple Companies 10.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics) 10.3.2.4.2. On-Off Switch (Theravectys) 10.3.2.5. Other Technologies to Improve CAR-T Safety 10.3.3. Allogeneic Technologies 10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals) 10.3.3.2. Allogeneic Platform (Celyad) 10.3.3.3. Allogeneic Platform (Cellectis) 11. CASE STUDY: CELL THERAPY MANUFACTURING 11.1. Chapter Overview 11.2. Introduction 11.3. Key Challenges 11.4. Current Trends 11.4.1. Companies with In-House Capabilities 11.4.2. Contract Manufacturers 11.5. Key Considerations for a Manufacturing Site 11.6. Regulatory Landscape 12. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS 12.1. Chapter Overview 12.2. Factors Contributing to the Price of Cell / Gene Therapies 12.3. Pricing Models for T-Cell Immunotherapies 12.3.1. On the Basis of Associated Costs 12.3.2. On the Basis of Competition 12.3.3. On the Basis of Patient Segment 12.3.4. On the Basis of Expert Opinions 12.4. Reimbursement Considerations for T-Cell Immunotherapies 12.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy 13. MARKET SIZING AND OPPORTUNITY ANALYSIS 13.1. Chapter Overview 13.2. Scope and Limitations 13.3. Forecast Methodology 13.4. Overall CAR-T Therapy Market 13.4.1. CAR-T Therapy Market: Distribution by Geography 13.4.2. CAR-T Therapy Market: Distribution by Target Indications 13.5. CAR-T Therapy Market: Product-Wise Sales Forecasts 13.5.1. Kymriah (Novartis) 13.5.2. Yescarta (Gilead Sciences) 13.5.3. bb2121 (Celgene / bluebird bio) 13.5.4. MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) 13.5.5. CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) 13.5.6. GPC3 CAR-T (Shanghai GeneChem) 13.5.7. TBI-1501 (Takara Bio / Jichi Medical University) 13.5.8. JCAR017 (Juno Therapeutics / Celgene) 13.5.9. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) 13.5.10. PCAR-019 (PersonGen BioTherapeutics) 13.5.11. AUTO2 (Autolus) 13.5.12. AUTO3 (Autolus) 13.5.13. BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) 13.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology / Henan Cancer Hospital) 13.5.15. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) 13.5.16. LCAR-B38M CAR-T (Nanjing Legend Biotech) 13.5.17. CD19 CAR-T (Shanghai Bioray Laboratory) 14. PROMOTIONAL ANALYSIS 14.1. Chapter Overview 14.2. Channels Used for Promotional Campaigns 14.3. Summary of Product Website Analysis 14.4. Summary of Patient Support Services and Informative Downloads 14.5. Kymriah: Promotional Analysis 14.6. Yescarta: Promotional Analysis 15. COMPANY PROFILES 15.1. Chapter Overview 15.2. Autolus 15.3. bluebird bio 15.4. CARsgen Therapeutics 15.5. Celgene 15.6. Cell Medica 15.7. Cellectis 15.8. Cellular Biomedicine Group 15.9. Innovative Cellular Therapeutics 15.10. Kite Pharma (A Gilead Sciences Company) 15.11. Novartis 15.12. Sinobioway Cell Therapy 15.13. Takara Bio 15.14. ZIOPHARM Oncology 16. CONCLUSION 16.1. CAR-T Therapies Market is Characterized by a Robust Pipeline of Over 350 Product Candidates Being Developed for Various Oncological Indications 16.2. The Primary Focus of CAR-Based Therapeutic Interventions is on Hematological Malignancies and Solid Tumors 16.3. Both Established Players and Start-Ups are Actively Involved in Developing CAR-T Therapies; Academic Institutes Continue to Make Significant Contributions to the Innovation in this Domain 16.4. Several Innovative Technology Platforms have been Developed, and are Expected to Enable the Development of Better Therapies, With Favorable Safety and Efficacy Profiles 16.5. Owing to High R&D Investments, CAR-T Therapies Bear Premium Price Tags; Developers are Striving to Offer Reimbursement Plans and Implement Various Promotional Strategies to Achieve Commercial Success 16.6. Post the Approval of Multiple Late-Phase Product Candidates, the Market is Anticipated to Grow at a Rapid Pace in the Foreseen Future 17. EXECUTIVE INSIGHTS 17.1. Chapter Overview 17.2. Enkhtsetseg Purev, Assistant Professor of Medicine, University of Colorado (Q1 2018) 17.3. Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology, Changhai Hospital (Q4 2017) 17.4. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing (Q1 2017) 17.5. Miguel Forte, Chief Operating Officer, TxCell (Q3 2016) 17.6. Adrian Bot, Vice President, Scientific Affairs, Kite Pharma (Q1, 2016) 17.7. Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys (Q3, 2015) 17.8. Vincent Brichard, Vice President, Immuno-Oncology, Celyad (Q3 2015) 18. APPENDIX 1: TABULATED DATA 19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/research/c...apies?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RealNex Navigator Upgrades Unveil Vast CRE Capabilities

Updated Category News Views 1

The Dawn of a New Navigator for CRE RealNex is unleashing a storm of enhancements to its Navigator platform, shaking up the commercial real estate (CRE) scene. Their latest upgrades are setting a new precedent for how brokers use technology to sharpen their game, handle transactions, and strategize in a market that never sleeps. Diving Deep into the Latest Upgrades First...

Continue Reading
Monib Zirvi's Dermatology Excellence Honored in 2026

Updated Category News Views 5

Trailblazer in Dermatology Recognized Again Fancy yourself a star in dermatology? Well, take notes from Dr. Monib A. Zirvi. The guy just got his due recognition from Marquis Who's Who for his sizable contributions to dermatology and research. For someone who's been at this game for over two decades, Zirvi doesn't just glide by on old merits. He's the real deal, and his...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 1

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading
Cove Capital Secures $9.96M for Debt-Free Logistics DST

Updated Category News Views 4

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 5

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Updated Category News Views 3

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

Continue Reading
Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

Updated Category News Views 2

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Continue Reading
RTI's $14M Boost: A Game-Changer for Tech Innovators

Updated Category News Views 0

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Continue Reading
Health Net's $2M Boost for Stanislaus Affordable Housing

Updated Category News Views 3

Joining the Fight Against California’s Housing Crisis Well, I'll be the first to say it's a breath of fresh air when a healthcare beast like Health Net starts investing in something as critical as affordable housing. This is no drop in the bucket—two million dollars is quite the commitment to fix some of the mess that’s been brewing in Stanislaus County, California....

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 0

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
More News Articles

Top 5 Most Recently Viewed Articles

Investigation Launched into F5, Inc. Over Security Concerns

Updated Category News Views 385

F5, Inc. Under Investigation for Securities Violations F5, Inc. (NASDAQ: FFIV) has recently come under scrutiny as an investigation has been launched regarding potential violations of U.S. federal securities laws. Concerns have arisen about whether the company and its executives made misleading statements or failed to disclose crucial information to investors. Details of...

Continue Reading
Verrica Pharmaceuticals Implements Cost-Cutting Restructuring

Updated Category News Views 40

Verrica Pharmaceuticals Takes Bold Steps for Improvement WEST CHESTER, Pa. - Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) has taken significant measures to move towards a more sustainable model amid challenges in the market. The company announced a strategic restructuring with the ambitious goal of cutting operational costs by around 50%. This strategic overhaul includes a...

Continue Reading
Sto Corp. Introduces Innovative Rainscreen System for Architects

Updated Category News Views 364

Sto Corp. Introduces the StoVentec Fiber Cement Rainscreen System Sto Corp., a leader in building envelope solutions, has recently launched their innovative StoVentec Fiber Cement Rainscreen System. This cutting-edge system transforms modern architecture by emphasizing sustainable practices, aesthetic flexibility, and top-tier performance. Performance and Versatility of...

Continue Reading
Promising Long-Term Effects of LEQEMBI on Alzheimer's Patients

Updated Category News Views 162

New Insights on LEQEMBI's Impact on Alzheimer's Disease Recent clinical data reveals significant findings regarding LEQEMBI (lecanemab-irmb) and its long-term benefits for patients with early-stage Alzheimer's disease (AD). Presenting these insights at a notable conference marked a key moment for both Eisai Co., Ltd. and Biogen Inc. These findings highlight how LEQEMBI...

Continue Reading
Innovative Payment Solutions: Native Teams Unveils Gig Pay Platform

Updated Category News Views 474

Native Teams Introduces Gig Pay for the Global Gig Economy In a significant development for the gig economy, Native Teams, a leading global platform for work payments, has launched Gig Pay, an innovative automated payroll and wallet solution. This groundbreaking service is designed to streamline compliance management while enhancing payment efficiency for gig workers...

Continue Reading